特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

市場アクセスへの影響 (欧州主要5ヶ国):リウマチ性関節炎 (RA)

Market Access Impact: [RA] Rheumatoid Arthritis (EU5) 2017

発行 FirstWord 商品コード 593143
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
詳細については [見積・お問合せ] ボタンよりお問い合わせ下さい。
市場アクセスへの影響 (欧州主要5ヶ国):リウマチ性関節炎 (RA) Market Access Impact: [RA] Rheumatoid Arthritis (EU5) 2017
出版日: 2017年11月01日 ページ情報: 英文
概要

当レポートでは、欧州主要5ヶ国 (EU5:フランス・ドイツ・イタリア・スペイン・英国) でリウマチ性関節炎 (RA) の治療に従事している医療専門家150名に対するアンケート調査の結果に基づいて、RA治療薬の利用に関する問題点について分析し、主要企業の市場シェア構造や、各社が現在直面している主な障害 (市場アクセスなど) とその原因・影響、取るべき対応策といった情報を取りまとめてお届けいたします。

リウマチ性関節炎 (RA) の主な治療薬

  • Benepali (エタネルセプト:Biogen)
  • Cimzia (セルトリズマブペゴル:UCB)
  • Enbrel (エタネルセプト:Pfizer)
  • Humira (アダリムマブ:AbbVie)
  • Inflectra (インフリキシマブ:Pfizer)
  • MabThera (リツキシマブ:Roche)
  • Orencia (アバタセプト:Bristol-Myers Squibb)
  • Remicade (インフリキシマブ:Merck Sharp & Dohme)
  • Remsima (インフリキシマブ:Napp/Mundipharma)
  • RoActemra (トシリズマブ:Roche)
  • Simponi (ゴリムマブ:Merck Sharp & Dohme)
  • Xeljanz (トファシチニブ:Pfizer)

目次

  • 「市場障壁」とは何か?
  • 当レポートについて
  • 今回の分析について
  • 調査対象のブランド
  • エグゼクティブ・サマリー
目次
Product Code: 596200807

Eliminating market barriers could help one brand almost double its market share

Market barriers have a modest but significant effect on rheumatoid arthritis (RA) prescriptions in the EU5. The brands that can find a way to eliminate them stand to make important share gains. Especially in the middle of the market, where competition is lively, and at the bottom of the market, where certain brands are poised to nearly double market share.

Find out which barriers are costing your brand market share in: Market Access Impact: Rheumatoid Arthritis (EU5).

Based on a survey of 150 rheumatologists, the report covers 12 major therapies from AbbVie, Biogen, Bristol-Myers Squibb, Merck Sharp & Dohme, Mundipharma, Napp, Pfizer, Roche, and UCB. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Not your market? Click here to see the US Edition.

Request sample pages

Top Takeaways

  • Nearly all brands are widely prescribed. Over 60% or more of the doctors surveyed prescribe nine of the 12 brands covered, and over 90% prescribe the top brand.
  • Six brands gain share. Two of them gain significantly while the other two barely gain at all.
  • Biosimilars are beginning to have an impact. The most prescribed biosimilar gains the most share overall, but others are struggling to capture physician interest.
  • Eliminating barriers would have the most impact on the bottom of the market. The brand that is prescribed the least is set to double its market share and move into 9th place.
  • Three brands have perception problems. Just over 20% of doctors surveyed would not consider prescribing those brands.
  • Market access is not the problem. Barriers related to market access affect far fewer prescriptions than either of the top two barriers.

Insight into 12 major RA drugs

  • Benepali (etanercept; Biogen)
  • Cimzia (certolizumab pegol; UCB)
  • Enbrel (etanercept; Pfizer)
  • Humira (adalimumab; AbbVie)
  • Inflectra (infliximab; Pfizer)
  • MabThera (rituximab; Roche)
  • Orencia (abatacept; Bristol-Myers Squibb)
  • Remicade (infliximab; Merck Sharp & Dohme)
  • Remsima (infliximab; Napp/Mundipharma)
  • RoActemra (tocilizumab; Roche)
  • Simponi (golimumab; Merck Sharp & Dohme)
  • Xeljanz (tofacitinib; Pfizer)

Exploring Market Access Barriers

Market Access Impact: Market Access Impact: Rheumatoid Arthritis (EU5) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 rheumatologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients in total in the last month

We conducted the survey between November 3-9, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Table of Contents

1.What are market barriers?

2.About this report

3.About the survey

4.Brands included in the survey

5.Executive summary